HLS Therapeutics Inc (HLTRF) Q3 2024 Earnings Call Highlights: Strategic Debt Reduction and ...

InvestingNov 8 11:01

HLS Therapeutics Inc Price Target Cut to C$3.25/Share From C$3.75 by Stifel Nicolaus

Dow JonesAug 13 23:54 · Ratings

HLS Therapeutics Q2 Net Loss Narrows With Cut in Expenses, Revenue Falls

MT NewswiresAug 8 19:58

Earnings Flash: HLS Therapeutics Q2 Revenue US$14.5 Million, Down From US$16.4 Million in 2023

MT NewswiresAug 8 19:16

Strategic Divestiture and Financial Flexibility: HLS Therapeutics Inc's Optimistic Buy Rating

TipRanksJul 3 20:35

Stifel Nicolaus Keeps Their Hold Rating on HLS Therapeutics Inc (HLS)

TipRanksJul 3 19:46